AI Engines For more Details: Perplexity Kagi Labs You
Lowering blood pressure: Doxazosin belongs to a class of medications known as alpha-1 blockers. It works by relaxing the muscles in the blood vessels, allowing them to dilate and reducing blood pressure. By reducing blood pressure, it helps prevent complications associated with hypertension, such as stroke, heart attack, and kidney problems.
Improving urinary symptoms: In men with benign prostatic hyperplasia (BPH), doxazosin helps relax the muscles in the prostate and bladder neck, making it easier to urinate. It can relieve symptoms such as difficulty starting urination, weak urine stream, and the need to urinate frequently or urgently.
Relaxation of smooth muscles: Doxazosin's mechanism of action involves blocking alpha-1 adrenergic receptors, which are found in smooth muscle tissue throughout the body. By blocking these receptors, it relaxes smooth muscles not only in blood vessels and the prostate but also in other organs and tissues, contributing to its therapeutic effects.
Reduction of urinary retention: Doxazosin can help reduce the risk of acute urinary retention, a condition where the bladder cannot empty, which is a common complication of BPH.
Potential for dizziness and fainting: One of the side effects of doxazosin is orthostatic hypotension, which is a sudden drop in blood pressure upon standing up from a sitting or lying position. This can lead to dizziness, lightheadedness, or fainting, especially when initiating treatment or increasing the dose.
Management of Raynaud's phenomenon: Doxazosin may also be used off-label for the management of Raynaud's phenomenon, a condition characterized by reduced blood flow to the fingers and toes in response to cold or stress.
Possible adjunctive therapy for heart failure: In some cases, doxazosin may be used as adjunctive therapy in the management of heart failure to help reduce symptoms and improve exercise tolerance, although other medications are typically preferred for this indication.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | -0.3 | |
| ADHD | 4.1 | 0.3 | 12.67 |
| Age-Related Macular Degeneration and Glaucoma | 0.9 | 0.4 | 1.25 |
| Allergic Rhinitis (Hay Fever) | 1.9 | 1.4 | 0.36 |
| Allergies | 5 | 2.3 | 1.17 |
| Allergy to milk products | 1.4 | 1.1 | 0.27 |
| Alopecia (Hair Loss) | 1.9 | 1.9 | |
| Alzheimer's disease | 2.8 | 5.8 | -1.07 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.5 | 1.4 | 1.5 |
| Ankylosing spondylitis | 4.4 | 0.8 | 4.5 |
| Anorexia Nervosa | 0.4 | 1.8 | -3.5 |
| Antiphospholipid syndrome (APS) | 1.4 | 1.4 | |
| Asthma | 0.7 | 1.7 | -1.43 |
| Atherosclerosis | 0.8 | 2.2 | -1.75 |
| Atrial fibrillation | 2.9 | 1.9 | 0.53 |
| Autism | 10.2 | 8.9 | 0.15 |
| Barrett esophagus cancer | 0.5 | 0.1 | 4 |
| benign prostatic hyperplasia | 0.4 | 0.4 | |
| Bipolar Disorder | 1 | 1.2 | -0.2 |
| Brain Trauma | 0.8 | 0.7 | 0.14 |
| Carcinoma | 3.1 | 2.6 | 0.19 |
| Celiac Disease | 2.9 | 3.3 | -0.14 |
| Cerebral Palsy | 1.5 | 0.9 | 0.67 |
| Chronic Fatigue Syndrome | 3.6 | 7.2 | -1 |
| Chronic Kidney Disease | 2 | 2.2 | -0.1 |
| Chronic Lyme | 0.7 | -0.7 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1 | 0.8 | 0.25 |
| Chronic Urticaria (Hives) | 2 | 1.9 | 0.05 |
| Coagulation / Micro clot triggering bacteria | 1.7 | 0.8 | 1.13 |
| Colorectal Cancer | 4.1 | 1.2 | 2.42 |
| Constipation | 1.5 | 0.7 | 1.14 |
| Coronary artery disease | 1.4 | 0.9 | 0.56 |
| COVID-19 | 10.9 | 11.8 | -0.08 |
| Crohn's Disease | 7.3 | 5.4 | 0.35 |
| cystic fibrosis | 1.2 | 1 | 0.2 |
| deep vein thrombosis | 1.2 | 0.6 | 1 |
| Depression | 8.3 | 9.2 | -0.11 |
| Dermatomyositis | 0.1 | 0.3 | -2 |
| Eczema | 1.3 | 1.6 | -0.23 |
| Endometriosis | 3.1 | 0.9 | 2.44 |
| Eosinophilic Esophagitis | 0.1 | 0.4 | -3 |
| Epilepsy | 2.8 | 3.2 | -0.14 |
| Fibromyalgia | 3.6 | 2.4 | 0.5 |
| Functional constipation / chronic idiopathic constipation | 4.9 | 3.7 | 0.32 |
| gallstone disease (gsd) | 2.3 | 0.8 | 1.87 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2 | 0.6 | 2.33 |
| Generalized anxiety disorder | 2 | 1.7 | 0.18 |
| giant cell arteritis | 0.4 | -0.4 | |
| Glioblastoma | 0.1 | -0.1 | |
| Gout | 0.3 | -0.3 | |
| Graves' disease | 1.4 | 1.6 | -0.14 |
| Halitosis | 0.7 | 0.1 | 6 |
| Hashimoto's thyroiditis | 2.4 | 0.5 | 3.8 |
| Hidradenitis Suppurativa | 0.2 | 0.4 | -1 |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 3.6 | 1 | 2.6 |
| hypercholesterolemia (High Cholesterol) | 0.9 | 0.7 | 0.29 |
| hyperglycemia | 0.4 | 2.2 | -4.5 |
| Hyperlipidemia (High Blood Fats) | 1.1 | 0.5 | 1.2 |
| hypersomnia | 0.2 | -0.2 | |
| hypertension (High Blood Pressure | 2.2 | 4.9 | -1.23 |
| Hypothyroidism | 0.9 | -0.9 | |
| Hypoxia | 1 | 1 | |
| IgA nephropathy (IgAN) | 3 | -3 | |
| Inflammatory Bowel Disease | 4.3 | 7.9 | -0.84 |
| Insomnia | 0.6 | 0.7 | -0.17 |
| Intelligence | 1 | 0.6 | 0.67 |
| Intracranial aneurysms | 0.9 | 0.5 | 0.8 |
| Irritable Bowel Syndrome | 4.5 | 4 | 0.13 |
| Liver Cirrhosis | 4.5 | 2.9 | 0.55 |
| Long COVID | 8.3 | 7 | 0.19 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.7 | 1.3 | -0.86 |
| ME/CFS with IBS | 1.3 | 2.4 | -0.85 |
| ME/CFS without IBS | 1.2 | 2.5 | -1.08 |
| Menopause | 1.5 | 1.5 | |
| Metabolic Syndrome | 7.9 | 8.6 | -0.09 |
| Mood Disorders | 11.3 | 9.2 | 0.23 |
| multiple chemical sensitivity [MCS] | 1 | 0.2 | 4 |
| Multiple Sclerosis | 3.6 | 5.4 | -0.5 |
| Multiple system atrophy (MSA) | 2.2 | 0.5 | 3.4 |
| Neuropathy (all types) | 0.7 | 0.4 | 0.75 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.3 | 1.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.6 | 4.9 | -0.88 |
| NonCeliac Gluten Sensitivity | 0.3 | -0.3 | |
| Obesity | 8.9 | 4.1 | 1.17 |
| obsessive-compulsive disorder | 5.8 | 4.6 | 0.26 |
| Osteoarthritis | 2.3 | 2.3 | |
| Osteoporosis | 1.4 | 1.1 | 0.27 |
| pancreatic cancer | 0.6 | 0.6 | |
| Parkinson's Disease | 3.4 | 3.1 | 0.1 |
| Polycystic ovary syndrome | 2.6 | 2 | 0.3 |
| Postural orthostatic tachycardia syndrome | 0.4 | 0.6 | -0.5 |
| Premenstrual dysphoric disorder | 1 | 0.4 | 1.5 |
| primary biliary cholangitis | 0.4 | 0.8 | -1 |
| Psoriasis | 4.9 | 3.5 | 0.4 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.9 | 4.2 | 0.4 |
| Rosacea | 0.7 | 0.9 | -0.29 |
| Schizophrenia | 6.3 | 1.7 | 2.71 |
| scoliosis | 0.3 | 0.3 | |
| Sjögren syndrome | 3.5 | 3 | 0.17 |
| Sleep Apnea | 0.9 | 1.3 | -0.44 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1 | 0.5 | 1 |
| Stress / posttraumatic stress disorder | 3.4 | 2.5 | 0.36 |
| Systemic Lupus Erythematosus | 3.9 | 1.5 | 1.6 |
| Tic Disorder | 1.4 | 1.7 | -0.21 |
| Tourette syndrome | 0.3 | 0.2 | 0.5 |
| Type 1 Diabetes | 3.5 | 2.5 | 0.4 |
| Type 2 Diabetes | 8.4 | 7.3 | 0.15 |
| Ulcerative colitis | 2.8 | 5.7 | -1.04 |
| Unhealthy Ageing | 5.3 | 2.9 | 0.83 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.